Learn more about YACC Canada and register for #primetown2021 at https://youngadultcancer.ca/program/primetown/
In partnership with CancerCare Manitoba and the CancerCare Manitoba Foundation, Young Adult Cancer Canada (YACC) is hosting Primetown, a virtual cancer summit for young adults and those who care for them.
From May 6-8, 2021, over 1,000 participants from coast to coast will attend digital workshops, keynotes, panels, social events, and more designed to help cope with cancer when you’re in the prime of life!
#Primetown2021 is a summit to empower and educate young adults with cancer and those who care for them. I urge everyone involved in the care of young adults with cancer to attend this event & make a difference in their lives. – Dr. Sapna Oberoi, Pediatric Oncologist & Researcher CCMB
- Registration for the Joint C17/MICYRN workshop on single patient studies is now open here: https://cvent.me/bOZq3D
- A randomised phase II study for patients with relapsed osteosarcoma is now available (OLIE study; IE +/- lenvatinib). More details available at https://mcusercontent.com/0a22c0fb4750c9511cde46055/files/3c6ef2e3-a6ed-483b-a89d-75349045675a/OLIE_investigator_referral_deck.pdf
- Venetoclax study now re-open for neuroblastoma and solid tumours (BCL-2 inhibitor plus chemotherapy)
- Slots available for DCL-17-001 phase I study of targeted radiotherapy for solid tumours, CNS and lymphoma
- ADVL1711 now open with available slots for rhabdomyosarcoma and HGG
- Ped-CITN-01 study open for any patient with hypermutant solid or CNS tumour
- Phase I study of oral BET inhibitor has available slots
Please note that despite COVID-19 restrictions, all NAIT studies continue to be open to enrollment
Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: firstname.lastname@example.org
Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.
Helping families navigate:
To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.
The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.
The Canadian Cancer Society and the Princess Margaret Cancer Centre invite young adults aged 19 – 39 with cancer to complete a survey about their experiences and needs throughout the cancer journey
The Canadian Cancer Society (CCS) and the Princess Margaret Cancer Centre (PMCC) invite young adults aged 19 – 39 with cancer to share their experiences and needs throughout the cancer journey. This survey will help CCS and PMCC better understand and address the unique care needs of young adults living with cancer.
Complete the survey at one of the links below:
English survey: https://external.redcap.uhn.ca/surveys/?s=A9TJR3T4EP
French survey: https://external.redcap.uhn.ca/surveys/?s=X9Y44PLEXE
Want to share – CCS’ social media posts about the survey:
If you have any questions about the survey or would like to get involved in our work with young adults, please contact Christine Harris at email@example.com.
See posting and application instructions at the link below. Application deadline is April 30, 2021.
JOB ID: 77148
Register TODAY: Canadian Consensus and Clinical Experience for Biomarker Testing and Treatment of TRK Fusion Cancer a free webinar hosted by C17 / Bayer April 21 2:30 PM EST
Register for free at: https://tinyurl.com/C17April21
Date: April 21st, 2021
Time: 2:30 – 4:00 PM EST (11:30 AM PT, 12:30 PM MT, 1:30 PM CT, 3:30PM AT)
Location: Virtual Zoom link to be shared after registration
C17 Council and Bayer Inc. invite you to participate in a presentation by:
Dr. Daniel Morgenstern, MB BChir PhD
Medical Director Oncology/BMTCT Clinical Trials Support Unit
Director New Agent and Innovative Therapy Program
Director Therapeutic MIBG Program
The Hospital for Sick Children, Toronto
Dr. Sébastien Perreault, MD, MSc, FRCPC
Department of Neurosciences, Faculty of Medicine, Université de Montréal
Director of the pediatric neurology program, CHU Sainte-Justine
Dr. Stephen Yip, MD, PhD, FRCPC
Clinician-Scientist/Consultant Neuropathologist, BCCA
Dr. Leah Young, PhD
PROFYLE and 3CTN Research Manager, C17 Council
Co-Founder of Ac2orn
Co-Founder of Neuroblastoma Canada
- Introduction to precision oncology and treatment in the context of pediatric patients in Canada
- Review the tumour agnostic nature of TRK inhibitors and the role and prevalence of NTRK fusions as oncogenic drivers in pediatric cancers
- Review of histology-specific pediatric algorithm (STS and CNS focused) for testing and treatment
- Parent/patient advocate involvement in making precision medicine and pediatric treatment option available
In accordance with IMC guidelines, this program is limited to Health Care Professionals and advocacy collaborators
C17 Council & AYA Program at the Princess Margaret Cancer Centre invite application for the Canadian AYA Oncology Operating Grant 2021, funded by the Michael Kamin Hart Foundation and Canadian Cancer Clinical Trials Network.
Forms can be downloaded from: https://tinyurl.com/C17Research
JOB POSTING: Pediatric Oncologist (Oncology and Stem Cell Transplant) at Alberta Children’s Hospital (apply by May 7, 2021)
Full posting and application instructions can be found at: DoctorJobsAlberta.com: Calgary – Pediatric Oncologist (Oncology and Stem Cell Transplant) – 40045
The Departments of Oncology and Pediatrics with Alberta Health Services (AHS) in conjunction with the Cumming School of Medicine and the University of Calgary invite applications for a full-time clinician in the Section of Pediatric Oncology/Transplant and Cellular Therapy (TCT), at the Clinical Assistant Professor level or higher. The successful applicant will become a member of the multidisciplinary pediatric oncology team located at the Alberta Children’s Hospital site of the Calgary Zone.
The successful candidate is expected to provide high quality in- and out-patient care to patients with oncologic disorders, including TCT patients working alongside a strong multidisciplinary team and will be expected to advance local, national and international collaborations.
Qualifications include an MD and eligibility for registration with the College of Physicians and Surgeons of Alberta. Certification in Pediatrics and Pediatric Hematology/Oncology are required. A candidate with a focus in Pediatric Oncology is preferred (while on service, coverage in TCT will be required) and a track record of productivity will be given preference for increased provision for protected research time. Specific interest and experience in clinical trials administration and operation will be an asset.
Single Patient Studies in Paediatrics: Challenges and Opportunities | Online workshop on Wednesday June 16 2-5 pm EDT | free registration required
Register at https://cvent.me/bOZq3D
Single patient protocols (SPS) are Health Canada approved clinical trials providing a means of accessing a novel therapy (or combination) that is not otherwise available. This online workshop will provide an overview of the regulatory context, outline the process of developing and implementing an SPS, and explore the opportunities and challenges of this approach in improving access to novel therapies for paediatric patients in Canada. The workshop is presented by C17 Council and MICRYN, together with Hospital for Sick Children, and will include representatives from regulators, study sponsors, pharma and other stakeholders.
- Health Canada perspective on SPS program and its relationship to special access program
- Review of oncology single patient studies undertaken to date
- The sponsor perspective on SPS
- Understanding the pharma perspective
- Challenges in the ethical review of SPS
- Expanding SPS beyond oncology
- Tackling the challenges of implementing SPS
- Practicalities of SPS protocol development
- Can we develop a national standard REB approach?
L’ACMTS lance un appel de candidatures pour son conseil d’administration et ses comités d’experts (experts et patientes)
L’ACMTS sollicite des candidatures pour des postes au sein de son conseil d’administration et de ses comités d’experts. Nous cherchons particulièrement des personnes dotées d’une expertise notable du système de santé canadien qui souhaitent aider les décideurs en soins de santé à faire des choix éclairés au sujet des technologies de la santé.
En tout, nous cherchons 15 nouveaux membres provenant de l’ensemble du pays et de différents domaines d’études, qui apporteront des expériences et des compétences diverses. Il s’agit d’une occasion en or de contribuer à faire du système de santé canadien le meilleur système qui soit.
Nous sollicitons des candidatures suivantes :
- au conseil d’administration de l’ACMTS – une personne du milieu universitaire et une personne du système de santé;
- au Comité canadien d’expertise sur les médicaments (CCEM) de l’ACMTS – quatre expertes ou experts et deux patientes ou patients;
- au Comité d’experts en examen du Programme pancanadien d’évaluation des anticancéreux (CEEP) de l’ACMTS – trois expertes ou experts et une patiente ou un patient;
- au Comité d’experts en examen sur les technologies de la santé (CEETS) de l’ACMTS – une présidente ou un président, une praticienne ou un praticien en soins de santé, une patiente ou un patient.
Vous trouverez tous les renseignements au sujet des fonctions, de l’admissibilité et de la mise en candidature sur le site Web de l’ACMTS.
Nous avons le plaisir d’offrir un processus de mise en candidature en ligne. Les candidatures doivent être soumises au moyen du formulaire en ligne au plus tard le 26 avril 2021.
Si vous ou l’une de vos connaissances répondez aux exigences d’un des postes à pourvoir, veuillez poser votre candidature ou inviter cette personne à poser la sienne. Merci d’avoir pris le temps d’examiner cette demande et d’en faire part aux candidats potentiels.
CADTH is seeking nominations for its Board of Directors and expert committees. We are currently accepting applications from individuals with significant expertise in the Canadian health care system who are interested in helping support health care decision-makers in making informed choices about health technologies.
In total, we are seeking 15 new members from across the country who have a range of education, experience, and skill sets. This is an exciting opportunity to help ensure that the Canadian health care system is the best it can be.
We are inviting nominations for the following:
- CADTH Board of Directors: 1 academic member and 1 health system member
- CADTH Canadian Drug Expert Committee (CDEC): 4 expert members and 2 patient members
- CADTH pCODR Expert Review Committee (pERC): 3 expert members and 1 patient member
- CADTH Health Technology Expert Review Panel (HTERP): 1 Chair, 1 health care practitioner, and 1 patient member.
Full details about each role, who is eligible to submit a nomination, and the nomination process are available on our website.
We are pleased to be offering an online nomination process. We ask that all interested individuals submit nominations via our online form by April 26, 2021.
If you, or someone you know, is suitable for one of the available roles, please submit a nomination, or encourage them to submit a nomination. Thank you for taking the time to consider this request, and for sharing it with potential candidates.